Market closed
Shattuck Labs/$STTK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Shattuck Labs
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Ticker
$STTK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
44
Website
Shattuck Labs Metrics
BasicAdvanced
$62M
-
-$1.49
1.67
-
Price and volume
Market cap
$62M
Beta
1.67
52-week high
$11.76
52-week low
$0.69
Average daily volume
249K
Financial strength
Current ratio
8.884
Quick ratio
8.185
Long term debt to equity
3.147
Total debt to equity
4.277
Management effectiveness
Return on assets (TTM)
-40.07%
Return on equity (TTM)
-67.23%
Valuation
Price to revenue (TTM)
11.534
Price to book
0.78
Price to tangible book (TTM)
0.78
Price to free cash flow (TTM)
-1.089
Growth
Revenue change (TTM)
245.26%
Earnings per share change (TTM)
-27.50%
3-year revenue growth (CAGR)
-42.45%
3-year earnings per share growth (CAGR)
11.56%
What the Analysts think about Shattuck Labs
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Shattuck Labs stock.
Shattuck Labs Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Shattuck Labs Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Shattuck Labs News
AllArticlesVideos
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
GlobeNewsWire·6 days ago
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
GlobeNewsWire·2 weeks ago
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Shattuck Labs stock?
Shattuck Labs (STTK) has a market cap of $62M as of April 08, 2025.
What is the P/E ratio for Shattuck Labs stock?
The price to earnings (P/E) ratio for Shattuck Labs (STTK) stock is 0 as of April 08, 2025.
Does Shattuck Labs stock pay dividends?
No, Shattuck Labs (STTK) stock does not pay dividends to its shareholders as of April 08, 2025.
When is the next Shattuck Labs dividend payment date?
Shattuck Labs (STTK) stock does not pay dividends to its shareholders.
What is the beta indicator for Shattuck Labs?
Shattuck Labs (STTK) has a beta rating of 1.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.